PCR’s Post

#Tricuspip field is moving quickly for the best of our patients! Beyond the direct comment of #TRISCENDII Edwards Lifesciences, recently presented at #TCT2024 Cardiovascular Research Foundation, you can find here the considerations of Prof Kodali Susheel about the #future of this field! 🔭 💫 Feel free to have a look at the report too 📰 : https://lnkd.in/dxZ2Rbmy #PCRTricuspid #TTVR PCR

🔥#PCRLV 🇬🇧 2024 Late-breaking Trials: Spotlight on TRISCEND II A study to ascertain whether Transcatheter Valve Replacement improves outcomes in symptomatic severe tricuspid regurgitation Outcome 📊: TTVR was superior to medical therapy for the primary composite outcome in adults with symptomatic severe TR #TreatTR #Tricuspidregurgitation #clinicaltrial #interventionalcardiology

Post hoc analysis of randomized clinical trial supports consideration of repeat selective laser trabeculoplasty in open-angle glaucoma regardless of initial response. https://ja.ma/48ezgnh

Top late-breaking trials presented today at #PCRLV 🎯 TRISCEND II trial: Evoque x medical therapy 👉 400 patients (2:1 randomization) 👉 1y Composite endpoint (death, RV assist device/ heart transplantation, TV intervention, HF hospitalization, improvement ≥ 10 points KCCQ-OS, improvement ≥ I NYHA, improvement ≥ 30 m 6-minute walk distance) favoring TTVR: win ratio 2.02 (95% CI, 1.56 to 2.62) 👉TTVR: ⬆️ severe bleeding 15.4% vs. 5.3%; new PPM 17.4% vs. 2.3% ⬇️ TR: mild or less TR in 95.3% 👉 Meaningful improvement in QoL

Knapik's group conducts a systematic review on clinical and radiologic outcomes for #meniscus tears treated nonoperatively with platelet-rich plasma (#PRP) and hypothesize that PRP would yield favorable patient-reported outcomes with low rates of complications. Their search yielded 6 studies in 184 patients with the use of injectable PRP for management of meniscal tears characterized as “chronic,” “degenerative,” or “intrasubstance" #PRP #degenerativemeniscus https://ow.ly/GwYL50Tuq5O

Case insights with Dr Michael Lichtenberg, MD on mechanical thrombectomy iliofemoral DVT treatment with Inari Medical's ClotTriever device. Dr. Lichtenberg discusses how device collects thrombus (clots) into a basket. The device pulls the thrombus slowly towards the sheath while the debris is collected in a collection bag. The device's basket is closed once it nears the funnel of the sheath, ensuring that the thrombus is safely captured and removed from the vessel without causing further embolization. The conversation highlights the effectiveness of the device in removing large clot burdens in a single session without the need for thrombolytics, minimizing the risk of bleeding complications. The treatment was performed on a patient with iliofemoral deep vein thrombosis (DVT), focusing on the non-invasive nature of the procedure compared to conventional methods. Dr. Lichtenberg emphasizes the high success rate and positive clinical outcomes with ClotTriever, recommending it for patients with extensive DVT in the iliofemoral region, particularly those who may not be good candidates for thrombolytic therapy. #DVT #venous #viocongress

📢 Exploring Holistic and Natural Treatment Options for Healing Using Your Own Cells. Using your own cells may be beneficial for certain medical conditions. Seen here, a Colorado Pain Care patient seeks therapy for the interosseous ligament of the SI joint using platelets. It was the patient’s choice and their own cells. Platelet-rich plasma (PRP) therapy is a medical treatment that involves using a concentration of a patient's own platelets to accelerate the healing of injured tendons, ligaments, muscles, and joints. This therapy uses injections of the patient’s own platelets to enhance the body's natural healing process. 👉 Pearls: • Patients are becoming more informed about orthobiologic options. • PRP is one of the few options. • Other options could come from your own bone marrow or fat. •The FDA is monitoring this closely. Ensure you understand the U.S. laws that define orthobiologics. #orthobiologics #prp #bonemarrowaspirate #bonemarrowconcentrate

Great insights on  #PAD Calcium Modification - A must read for anyone involved in Leg Angioplasty Shockwave Medical #IVL #PAD #CLTI #L6

The Ultrasept PFO Occluder (Encore Medical INC) is characterized by the following elements: - Double-disc pfo occlusion device with a central tuft to improve acute closure - Super low profile - Biotome release system - Septal puncture friendly to perform interventional activities in the left heart - Fully retrievable and repositionable CLOSE Trial The Ultrasept pfo occluder device has been studied in CLOSE Trial, a multicenter, randomized trial where 663 patients who had a recent cryptogenic stroke attributed to PFO with an interatrial septal aneurysm or significant interatrial shunt were analyzed. The rate of stroke recurrence was lower among patients undergoing PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone. https://lnkd.in/dgkq_yRk

💓 Reflow Medical recruits first patient in Spur Elute trial for in-stent restenosis The study, known as DEEPER CORONARY, will recruit 10 patients at up to three centres in New Zealand. New Zealand’s Wellington Hospital interventional cardiologist and trial principal investigator Scott Harding said: “It’s exciting to take part in the study of this novel platform, which has the potential to successfully treat patients suffering from in-stent restenosis.” Spur Elute addresses coronary ISR in patients by delivering a proprietary sirolimus drug formulation directly to the affected lesion without the use of a permanent metallic implant. Read more online: https://lnkd.in/ebBpZ3y4 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing